Overall, treatment with clodronate was associated with a highly significant reduction in the rates of bone loss at the two sites compared to placebo (femoral neck BMD % change, −1.51 ± 6.55 versus −3.44 ± 6.24, p < 0.001; total hip BMD % change, −1.57 ± 6.18 versus −4.10 ± 7.14, p <0 .001, Fig. 2 ).
2 ); within the women receiving clodronate, the loss of BMD in those receiving NSAIDs was greater than that observed in those not receiving NSAIDs, though this did not quite reach statistical significance ( p = 0.078) for the total hip.
Within this RCT, we have been able to examine the impact of NSAIDs on compliance with clodronate, and while the median intake and proportion showing high compliance were slightly lower in NSAID users, this did not reach statistical significance and is highly unlikely to explain the observations.